Department of Medical Oncology Ward 3, Affiliated Hangzhou Cancer Hospital, Hangzhou, 310002, Zhejiang, China.
Department of Thoracic Oncology, Affiliated Hangzhou Cancer Hospital, Hangzhou, 310002, Zhejiang, China.
Support Care Cancer. 2024 Apr 22;32(5):300. doi: 10.1007/s00520-024-08499-y.
We evaluated the efficacy of megestrol in improving chemotherapy-related anorexia by analyzing the related scales of taste alteration.
We conducted the current study on a group of advanced patients with cancer with two or more chemotherapy cycles. The chemotherapy-induced taste alteration scale (CiTAs) scale helped assess the megestrol effects on basic taste perception, aversive taste changes, unpleasant symptoms, and associated concerns. Furthermore, the Short Nutritional Assessment Questionnaire scale (SNAQ) helped measure the impact of megestrol on malnutrition likelihood in patients experiencing chemotherapy-induced anorexia. The World Health Organization Quality of Life (WHOQOL)-BREF Scale was used to evaluate the quality of life of participants, producing scores related to physical health, psychological well-being, environmental factors, and social relationships.
The CiTAs scale assessment indicated that administering megestrol significantly enhanced taste perception among advanced patients with cancer undergoing chemotherapy. Notably, the megestrol group patients showed significantly higher Short Nutritional Assessment Questionnaire (SNAQ) scores than the control group. The megestrol group patients also exhibited higher physiological (PHYS) scores than their control group counterparts. However, this distinction was not statistically significant. The study findings indicate that patients who received megestrol demonstrated significantly higher scores in psychological (PSYCH) and environmental(ENVIR) domains than the control group. Furthermore, megestrol administration was associated with significantly elevated SOCIL and ENVIR levels in patients.
The proficient efficacy evaluation of megestrol in enhancing appetite, mitigating malnutrition likelihood, and improving the quality of life of chemotherapy-induced anorexic patients can be achieved through taste-related scales.
通过分析味觉改变相关量表，评估美曲孕酮改善化疗相关性厌食的疗效。
本研究纳入了 2 个或更多化疗周期的晚期癌症患者。化疗诱导的味觉改变量表（CiTAs）评估美曲孕酮对基本味觉感知、味觉厌恶改变、不适症状和相关问题的影响。此外，简短营养评估问卷（SNAQ）评估美曲孕酮对化疗诱导性厌食患者发生营养不良的影响。采用世界卫生组织生存质量测定量表简表（WHOQOL-BREF）评估参与者的生活质量，得出与身体健康、心理健康、环境因素和社会关系相关的评分。
CiTAs 量表评估表明，美曲孕酮可显著改善化疗中晚期癌症患者的味觉感知。美曲孕酮组患者的短营养评估问卷（SNAQ）评分明显高于对照组。美曲孕酮组患者的生理（PHYS）评分也高于对照组，但差异无统计学意义。研究结果表明，接受美曲孕酮治疗的患者在心理（PSYCH）和环境（ENVIR）领域的评分明显高于对照组。此外，美曲孕酮治疗与患者社会关系（SOCIL）和环境（ENVIR）评分的显著升高相关。
通过味觉相关量表可对美曲孕酮改善化疗相关性厌食患者的食欲、降低营养不良风险和提高生活质量进行有效的疗效评估。
